Insights from the PRECISE Trial 1-Year Data: Optimizing CAD Assessment for Improved Outcomes
Watch now!
The 1-year results from the PRECISE Trial were presented by Dr. Pamela Douglas in a Late Breaking Science session at the American Heart Association (AHA) annual congress in Chicago on November 6th. This global, prospective, randomized trial examined a Precision Pathway versus a Traditional Testing pathway for patients with stable chest pain. The Precision Pathway included risk stratification using the PROMISE risk score, deferred testing in low-risk patients and CCTA and selective FFRct in elevated risk patients.